Louise Chen
Stock Analyst at Scotiabank
(0.92)
# 2,429
Out of 4,827 analysts
299
Total ratings
28.57%
Success rate
-18.97%
Average return
Main Sectors:
Stocks Rated by Louise Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACRS Aclaris Therapeutics | Maintains: Sector Outperform | $15 → $9 | $1.27 | +608.66% | 6 | May 9, 2025 | |
| EWTX Edgewise Therapeutics | Downgrades: Sector Perform | $50 → $14 | $14.57 | -3.91% | 2 | Apr 3, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Sector Perform | $105 → $80 | $36.28 | +120.54% | 2 | Mar 20, 2025 | |
| GANX Gain Therapeutics | Initiates: Sector Outperform | $12 | $1.93 | +521.76% | 1 | Mar 7, 2025 | |
| INVA Innoviva | Initiates: Sector Outperform | $55 | $18.56 | +196.42% | 5 | Mar 7, 2025 | |
| BPMC Blueprint Medicines | Initiates: Sector Outperform | $150 | $97.19 | +54.34% | 1 | Mar 7, 2025 | |
| PTCT PTC Therapeutics | Initiates: Sector Perform | $55 | $44.19 | +24.46% | 1 | Mar 7, 2025 | |
| CATX Perspective Therapeutics | Initiates: Sector Outperform | $15 | $2.33 | +543.78% | 1 | Mar 7, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Sector Outperform | $50 | $22.87 | +118.63% | 1 | Mar 7, 2025 | |
| ARDX Ardelyx | Initiates: Sector Outperform | $15 | $3.63 | +313.79% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $17 | $4.83 | +252.33% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $70 | $27.90 | +150.90% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $11.44 | +337.25% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $30 | $13.44 | +123.21% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $55 | $29.26 | +87.97% | 8 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.62 | - | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $160 | $65.71 | +143.49% | 20 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $31.15 | - | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $45 | $22.29 | +101.88% | 31 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $153.97 | +39.64% | 40 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.88 | - | 5 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $75.95 | +104.08% | 25 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $10.65 | - | 9 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $885 | $739.83 | +19.62% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $9.80 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $14.05 | - | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $11.00 | - | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.10 | - | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $18.75 | - | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $200 | $184.28 | +8.53% | 5 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.81 | - | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.89 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $10.40 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.19 | - | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $925 | $527.69 | +75.29% | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.95 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $6.97 | +833.24% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $0.81 | +517.44% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $0.86 | +2,820.56% | 4 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $14.22 | +251.74% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $13.51 | +270.23% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.47 | +240.14% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $9 | $1.29 | +600.39% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,687,500 | $8.41 | +20,065,298.34% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $258 | $454.38 | -43.22% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $15 | $16.93 | -11.37% | 3 | Feb 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $2.11 | +2,269.67% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.26 | +1,493.63% | 2 | Aug 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $6.83 | +558.86% | 1 | Jun 22, 2017 |
Aclaris Therapeutics
May 9, 2025
Maintains: Sector Outperform
Price Target: $15 → $9
Current: $1.27
Upside: +608.66%
Edgewise Therapeutics
Apr 3, 2025
Downgrades: Sector Perform
Price Target: $50 → $14
Current: $14.57
Upside: -3.91%
Sarepta Therapeutics
Mar 20, 2025
Maintains: Sector Perform
Price Target: $105 → $80
Current: $36.28
Upside: +120.54%
Gain Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $1.93
Upside: +521.76%
Innoviva
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $18.56
Upside: +196.42%
Blueprint Medicines
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $150
Current: $97.19
Upside: +54.34%
PTC Therapeutics
Mar 7, 2025
Initiates: Sector Perform
Price Target: $55
Current: $44.19
Upside: +24.46%
Perspective Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $2.33
Upside: +543.78%
Palvella Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $22.87
Upside: +118.63%
Ardelyx
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $3.63
Upside: +313.79%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $17
Current: $4.83
Upside: +252.33%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $70
Current: $27.90
Upside: +150.90%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $11.44
Upside: +337.25%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $30
Current: $13.44
Upside: +123.21%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $29.26
Upside: +87.97%
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.62
Upside: -
Nov 6, 2024
Reiterates: Overweight
Price Target: $160
Current: $65.71
Upside: +143.49%
Nov 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $31.15
Upside: -
Oct 25, 2024
Reiterates: Overweight
Price Target: $45
Current: $22.29
Upside: +101.88%
Oct 16, 2024
Reiterates: Overweight
Price Target: $215
Current: $153.97
Upside: +39.64%
Oct 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.88
Upside: -
Oct 3, 2024
Reiterates: Overweight
Price Target: $155
Current: $75.95
Upside: +104.08%
Sep 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.65
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $885
Current: $739.83
Upside: +19.62%
Sep 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.80
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $14.05
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.00
Upside: -
Aug 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.10
Upside: -
Aug 14, 2024
Reiterates: Overweight
Price Target: n/a
Current: $18.75
Upside: -
Aug 5, 2024
Reiterates: Overweight
Price Target: $200
Current: $184.28
Upside: +8.53%
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.81
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.89
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.40
Upside: -
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.19
Upside: -
Apr 15, 2024
Reiterates: Neutral
Price Target: $925
Current: $527.69
Upside: +75.29%
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.95
Upside: -
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $6.97
Upside: +833.24%
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $0.81
Upside: +517.44%
Sep 5, 2023
Reiterates: Overweight
Price Target: $25
Current: $0.86
Upside: +2,820.56%
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $14.22
Upside: +251.74%
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $13.51
Upside: +270.23%
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.47
Upside: +240.14%
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $1.29
Upside: +600.39%
Jul 7, 2021
Initiates: Overweight
Price Target: $1,687,500
Current: $8.41
Upside: +20,065,298.34%
Mar 27, 2020
Maintains: Neutral
Price Target: $240 → $258
Current: $454.38
Upside: -43.22%
Feb 12, 2020
Maintains: Neutral
Price Target: $9 → $15
Current: $16.93
Upside: -11.37%
Jul 19, 2018
Maintains: Overweight
Price Target: $40 → $50
Current: $2.11
Upside: +2,269.67%
Aug 18, 2017
Initiates: Overweight
Price Target: $20
Current: $1.26
Upside: +1,493.63%
Jun 22, 2017
Initiates: Overweight
Price Target: $45
Current: $6.83
Upside: +558.86%